Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,

Slides:



Advertisements
Similar presentations
Effect of detorsion alone and in combination with enoxaparin therapy on ovarian reserve and serum antimüllerian hormone levels in a rat ovarian torsion.
Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates  Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.
Akanksha Mehta, M.D., Mark Sigman, M.D.  Fertility and Sterility 
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Michael M. Alper, M.D.  Fertility and Sterility 
Preconception risk stratification before fertility care
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist 
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Medical treatment of ectopic pregnancy: a committee opinion
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.
Oocyte cryopreservation
Klinefelter's syndrome with unilateral absence of vas deferens
Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant?  H. Browne, A. Armstrong,
Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH)  P. Barriere, T. Freour, D. Masson,
Efficacy of tibolone as “add-back therapy” in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids  Edward.
Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review  Seema Menon, M.D., John.
Robert F. Casper, M.D.  Fertility and Sterility 
Amir M. Khan, M. D. , Sunit Jariwala, M. D. , Harry Jay Lieman, M. D
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis  Laura P. Smith, M.D.,
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Clomiphene citrate at 50: the dawning of assisted reproduction
Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case  Jorge Burgos, M.D., Patricia.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist 
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Effect of weight loss after Roux-en-Y gastric bypass surgery on the male reproductive hormonal profile  A.O. Hammoud, M. Gibson, S.C. Hunt, D. Carrell,
Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists  José M. López, M.D., Eveline.
P-425 Fertility and Sterility Volume 86, Issue 3, (September 2006)
A case of ovarian hyperstimulation syndrome associated with the methylenetetrahydrofolate reductase mutation gene  Filippo Ferrara, M.D., Francesco Meli,
Cabergoline and Ganirelix Therapy for Early Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) Results in Faster Recovery than in Early Untreated.
L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing 
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
Fertility and Sterility: an evaluation
Paolo Moghetti, M.D.  Fertility and Sterility 
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Sedigheh Borna, M.D., Azita Nasery, M.D.  Fertility and Sterility 
Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss  Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Ovarian cystic teratoma with a pathognomonic appearance of multiple floating balls: a case report and investigation of common characteristics of the cases.
Current evaluation of amenorrhea
Genetic evaluation procedures at sperm banks in the United States
Fertility and Sterility
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Ronald M. Yang, M. D. , Richard A. Fefferman, M. D. , Charles E
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
In vitro sildenafil citrate use as a sperm motility stimulant
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy  Eman A. Elgindy,
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Presentation transcript:

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene, M.D., Mark H. Amols, M.D., Susan B.A. Hudson, M.D., Charles C. Coddington, M.D.  Fertility and Sterility  Volume 92, Issue 3, Pages 1169.e15-1169.e17 (September 2009) DOI: 10.1016/j.fertnstert.2009.05.062 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Weight loss after treatment with cabergoline and ganirelix. Day 0 is the day cabergoline and ganirelix were administered. No weights were recorded for case 2. Fertility and Sterility 2009 92, 1169.e15-1169.e17DOI: (10.1016/j.fertnstert.2009.05.062) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.